Navigation Links
Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease
Date:2/26/2010

, a human cell line derived enzyme replacement therapy (ERT) for the long-term treatment of Type 1 Gaucher disease in pediatric and adult patients. The FDA designated VPRIV for Priority Review and granted marketing approval in just 6 months. VPRIV offers patients and their physicians a new treatment option at a critical time, as the supply of the previously approved ERT for Gaucher disease is uncertain and remains disrupted.

"We have had the opportunity to use VPRIV in clinical trials and actively participated in the expanded access program. We appreciate the support Shire's management team has provided during the last few months to ensure continuity of care for nearly 50 of our patients with Gaucher disease. We are confident the team Shire has put into place will ensure a seamless transition into the post-regulatory period," said Gregory M. Pastores MD, Associate Professor of Neurology and Pediatrics at the NYU School of Medicine in New York. "VPRIV offers patients a therapeutic option that is safe and effective, and our experience with VPRIV has helped build confidence in its use, bolstered by data on low frequency of antibody formation."

Shire recognizes that the treatments it develops for life-altering diseases and conditions require specialized service and support offerings. With today's FDA approval of VPRIV, the company has implemented enhancements to its existing OnePathSM Access Program with the introduction of a new Co-Pay Assistance Program. The new program was devel
'/>"/>

SOURCE Shire Pharmaceutical
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
2. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
3. Shire Divests Non-Core Product Portfolio to Almirall
4. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
5. David Mott Appointed Non Executive Director at Shire
6. Shire plc: Board Changes
7. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
8. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
9. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
10. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
11. Shire Engages Palio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2014)... USA (PRWEB) September 20, 2014 Entries ... 2015 Prism Awards for Photonics Innovation . The ... the multi-billion dollar optics and photonics industry, and is ... and photonics , and Photonics Media . , ... the versatility of photonics, said SPIE CEO Eugene Arthurs. ...
(Date:9/19/2014)... YORK, September 18, 2014 Scientists at NYU Langone ... dramatically the efficiency of the process for turning adult ... well-known compounds, including vitamin C. Using the new technique ... cells obtained from adult skin cells by more than ... technique is efficient and reliable, and thus should generally ...
(Date:9/19/2014)... FRANCISCO , Sept. 19, 2014  Nektar ... results from preclinical studies characterizing the analgesic profiles ... peripherally-acting kappa opioid receptor agonist molecules. The preclinical ... polymer medicinal chemistry platform. The analgesic ... in the medical literature. 1,2 Kappa opioid ...
(Date:9/19/2014)... , September 19, 2014 ... Markets ( http://www.researchandmarkets.com/research/b2jxhs/micro_market ) has announced the addition of ... Columns"  report to their offering.       ... is one of the fastest-growing segments in the ... billion in 2013, and expected to reach $2.0 ...
Breaking Biology Technology:Entry deadline is 10 October for international photonics Prism Awards 2Entry deadline is 10 October for international photonics Prism Awards 3Entry deadline is 10 October for international photonics Prism Awards 4NYU Langone scientists report reliable and highly efficient method for making stem cells 2NYU Langone scientists report reliable and highly efficient method for making stem cells 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 5Micro Market Monitor : Global Pre-packed Chromatography Columns 2
... Broadway Hotel in New York on Thursday, ... ... Inc. (Nasdaq:,FVRL), a biopharmaceutical company developing patient-specific, active,immunotherapies for the treatment ... Executive Officer, will present at,the NewsMakers in the Biotech Industry investment ...
... Belgium, August 24 ThromboGenics NV (Euronext,Brussels: THR), ... a business update and its financial results for ... this period, ThromboGenics has raised,additional funds to invest ... good progress with its clinical programs. Highlights ...
... Stem cell company,Neuralstem, Inc. (OTC Bulletin Board: NRLS) ... on the American Stock Exchange(R) (Amex(R)),under the symbol CUR. ... August 27, 2007. "Moving to the Amex is ... of the continuous and significant progress the company has ...
Cached Biology Technology:Favrille CEO to Present at NewsMakers in the Biotech Industry Investment Conference 2ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007 2ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007 3ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007 4ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007 5ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007 6ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007 7ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007 8ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007 9ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007 10ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007 11Neuralstem Shares Accepted for Trading on Amex(R) 2
(Date:9/21/2014)... T cells may have the ability to trigger an ... led by King,s College London. Although their immune system ... still be able to mount a strong immune defense, ... Medicine . , Our immune system is made up ... which play an important role in the frontline defense ...
(Date:9/19/2014)... by researchers from several Harvard University labs in ... and aspiring researchers with the intellectual raw materials ... from soft, flexible materials. , With the advent ... advances in manufacturing technology, soft robotics is emerging ... from conventional rigid robot design, but working with ...
(Date:9/19/2014)... you are a species which over thousands of years has ... to a substance that makes the cold dangerous for you. ... Enchytraeus albidus , and the cold provoking substance, called nonylphenol, ... , Nonylphenol is suspected of being a endocrine disruptor, but ... inhibits the worm,s ability to protect the cells in its ...
Breaking Biology News(10 mins):Immune system of newborn babies is stronger than previously thought 2Soft robotics 'toolkit' features everything a robot-maker needs 2Environmental pollutants make worms susceptible to cold 2Environmental pollutants make worms susceptible to cold 3
... of Preventive Medicine (ACPM) has launched a web ... medicine the practice of changing health behaviors to ... The document summarizes scientific evidence supporting lifestyle interventions. ... such as definitions, reimbursement trends, related practice patterns, ...
... advent of the Human Genome Project an explosion of data ... demand to fine-tune genomic codes, which list the "ingredients for ... A Rutgers UniversityCamden biochemist is addressing this ... "background checks" on all known enzyme functions. Thanks to ...
... increases in obesity and associated diseases -- and fiery debates ... team has identified a new genetic mechanism that controls the ... to new treatments for obesity and type 2 diabetes, and ... people and dramatically cut health care costs. A research ...
Cached Biology News:American College of Preventive Medicine releases lifestyle medicine literature review 2Rutgers-Camden developing enzyme function database 2UCF discovery could open door to obesity, diabetes treatments 2
... The ProteoSpin Detergent Clean-up Micro Kit provides ... removal of SDS, Triton X-100 and other detergents ... spin-column chromatography using Norgens patented protein resin as ... processing 2 50 g of either acidic or ...
Compound(s) screened through any number of client selected assays. Client also selects number of concentrations and replicates....
... hematopoietic stem cells called monocytes. Osteoclasts resorb ... and lowering the surrounding pH to an ... mineral is then solubilized and the collagen ... primarily by Macrophage Colony-Stimulating Factor (M-CSF) and ...
Values of steady state parameters for enzyme activities are determined....
Biology Products: